Etiology and treatment of cough in idiopathic pulmonary fibrosis

Vigeland, C.L.; Hughes, Andrew; Horton, Maureen R.

doi:10.1016/j.rmed.2016.12.016

Cited by 34 publications

(28 citation statements)

References 79 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the majority of patients, cough is among the first symptoms, often preceding dyspnoea on exertion, sometimes by years [61]. Cough in IPF patients is more common during the day and rarely wakens the patients from sleep, consistent with the diurnal variation reported in many chronic respiratory disorders [62]. Cough may coexist or be exacerbated by comorbid illnesses such as gastro-oesophageal reflux, despite its treatment [63], and is generally refractory to medical therapy [48].…”

Section: Coughmentioning

confidence: 87%

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Ferrara

Luppi²,

Birring

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and optimise quality of life (QoL) in patients affected by progressive diseases. In this sense, it excludes and might be complementary to other interventions directly targeting the disease. BSC improves survival in patients with different types of cancer. Patients with idiopathic pulmonary fibrosis (IPF) experience a vast range of symptoms during the natural history of the disease and might have a beneficial effect of BSC interventions. This review highlights the current evidence on interventions targeting QoL and gaps for the clinical assessment of BSC in the treatment of IPF patients. Very few interventions to improve QoL or improve symptom control are currently supported by well-designed studies. Sound methodology is paramount in evaluating BSC in IPF, as well as the use of validated tools to measure QoL and symptom control in this specific group of patients.

show abstract

Section: Coughmentioning

confidence: 87%

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Ferrara

Luppi²,

Birring

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…A few studies assessed drugs specifically targeting cough in IPF. 66 Talidomide treatment was associated with a decrease in cough and an increase in respiratory QoL. 105 A positive effect of interferon-α was suggested in a small trial.…”

Section: Refractory Chronic Cough: Recent Advancesmentioning

confidence: 99%

“…Chronic cough affects 70%–85% of patients with IPF, has a significant impact on QoL and is a marker of disease severity and progression. 66 Its mechanisms and therapeutic options have been recently reviewed. 66 …”

Section: Other Causes To Considermentioning

confidence: 99%

Managing patients with chronic cough: challenges and solutions

Perotin-Collard¹,

Claire²,

Dewolf³

et al. 2018

TCRM

View full text Add to dashboard Cite

Chronic cough is a common complaint and a frequent cause of medical consultation. Its management can be difficult. We present here an overview of the current guidelines for the management of chronic cough. Different steps are detailed, including the initial research of an obvious etiology and alert signs that should lead to further investigation of underlying condition. The diagnosis of the most frequent causes: asthma, non-asthmatic eosinophilic bronchitis, gastroesophageal reflux disease and upper airway cough syndrome should be considered, assessed and treated accordingly. Recent advances have been made in the comprehension of refractory chronic cough pathophysiology as well as its pharmacologic and non-pharmacologic treatment, especially speech pathology therapy.

show abstract

“…Patients with IPF can show a reduction in cough with the use of thalidomide (100 mg p.o., once a day), although that drug is not approved for use in Brazil. 63 …”

Section: Symptom Management In Patients With Respiratory Diseasesmentioning

confidence: 99%

Palliative care in pulmonary medicine

Oliveira¹,

Medeiros²

2020

J Bras Pneumol.

View full text Add to dashboard Cite

Palliative care was initially developed for patients with advanced cancer. The concept has evolved and now encompasses any life-threatening chronic disease. Studies carried out to compare end-of-life symptoms have shown that although symptoms such as pain and dyspnea are as prevalent in patients with lung disease as in patients with cancer, the former receive less palliative treatment than do the latter. There is a need to refute the idea that palliative care should be adopted only when curative treatment is no longer possible. Palliative care should be provided in conjunction with curative treatment at the time of diagnosis, by means of a joint decision-making process; that is, the patient and the physician should work together to plan the therapy, seeking to improve quality of life while reducing physical, psychological, and spiritual suffering.

show abstract

Etiology and treatment of cough in idiopathic pulmonary fibrosis

Cited by 34 publications

References 79 publications

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions

Managing patients with chronic cough: challenges and solutions

Palliative care in pulmonary medicine

Contact Info

Product

Resources

About